Edwards Lifesciences (EW) Q1 2024 Earnings
Edwards Lifesciences reported Q1 2024 revenue of $1.6B, beat analyst consensus of $1.6B by $28.2M. Diluted EPS came in at $0.66, beat the $0.64 consensus by $0.02. Edwards Lifesciences reports across 4 business segments, led by Transcatheter Aortic Valve Replacement (TAVR), Surgical Structural Heart, and Transcatheter Mitral and Tricuspid Therapies (TMTT).
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about Edwards Lifesciences's Q1 2024 earnings report.
Edwards Lifesciences (EW) reported Q1 2024 earnings on April 25, 2024 after market close.
Edwards Lifesciences reported revenue of $1.6B and diluted EPS of $0.66 for Q1 2024.
Revenue beat the consensus estimate of $1.6B by $28.2M. EPS beat the consensus estimate of $0.64 by $0.02.
You can read the 10-Q periodic report (0001099800-24-000039) directly on SEC EDGAR. The filing index links above go to sec.gov.